Related Experiment Video
Updated: May 19, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice
Christoph U Correll1, Juan A Gallego
1The Zucker Hillside Hospital, Division of Psychiatry Research, North Shore-LIJ Health System, 75-59, 263rd Street, Glen Oaks, NY 11004, USA. ccorrell@lij.edu
Abstract:
Antipsychotic polypharmacy (APP) is common in the treatment of schizophrenia spectrum disorders. The literature indicates that APP is related to patient, illness, and treatment variables that are proxy measures for greater illness acuity, severity, complexity, and chronicity. The largely unknown relative risks and benefits of APP need to be weighed against the known risks and benefits of clozapine for treatment-resistant patients. To inform evidence-based clinical practice, controlled, high-quality antipsychotic combination and discontinuation trials are necessary to determine the effectiveness, safety, and role of APP in the management of severely ill patients with insufficient response to antipsychotic monotherapy.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Drug Dosing: Geriatric Patients
Antipsychotic Drugs: Typical and Atypical Agents
Drug Toxicity: Risk factors
